NKGen's Alzheimer's Pitch Runs Into a Nearly Empty Balance Sheet

The headline is easy to read as good news. NKGen Biotech is set to present its lead cell therapy, troculeucel, at a biomanufacturing conference in Korea — a chance to pitch the drug's potential across Alzheimer's, Parkinson's, ALS, and frontotemporal dementia to an international audience. For a beginner scanning the ticker, that looks like a company building toward a real product.

It is. The science is the one part of this story worth taking seriously. And it is not what decides whether the common stock compounds.

A real signal hidden in a tiny, uncontrolled study

Troculeucel is what's called an autologous NK cell therapy — a treatment that takes a patient's own natural killer cells, expands them in a lab, and reinfuses them to tamp down neuroinflammation. In two small, open-label Phase 1 trials, results that management has now pooled and presented repeatedly looked encouraging: 92% of Alzheimer's patients showed stable or improved cognitive function, and in a six-patient moderate-disease subgroup, all six held or improved while half moved from moderate to mild on a standard cognitive scale. Biomarker signals tracked the story, including reductions in GFAP, a protein tied to dementia severity.

Here is the honest read: no placebo arm, a handful of patients, still-early data. That is a reason to keep watching, not a verdict. But it is real, and it is the entire bull case.

The operating reality is not a growth story

The investment case, however, is not made by the slides this CEO presents on a conference circuit that recycles the same small dataset. It is made by the financial statements, and those tell a different story.

At the most recent reported balance sheet, NKGen had roughly $100,000 of cash against an operating burn on the order of $20 million a year. Run the arithmetic and you get about two days of runway — call it measured in days, not months, at that snapshot. The company carries tens of millions in debt against negative shareholder equity of more than $47 million, meaning assets no longer cover liabilities. On the equity side, the entire market capitalization has fallen to a few hundred thousand dollars — down more than 97% in a single year — even as the enterprise (equity plus debt) remains in the tens of millions, because the creditors and the structure, not the common shareholders, hold the value.

This is why the company no longer trades on the Nasdaq. It was moved to the OTC market in March 2025.

How a company with no cash survives: small, dilutive deals

The way NKGen has actually financed itself tells a shareholder everything. In July 2025 it raised $2 million from a strategic investor. In September it added a $1.05 million secured convertible note that converts into more than 13 million shares at $0.08 apiece, bundled with a ten-year $0.08 warrant and a voting arrangement among large holders to increase authorized shares. Amounts this small, at a conversion price well below where the stock had traded, are not growth capital. They buy weeks of survival, and every one of them is paid for by existing shareholders through dilution.

Here the bull case and the bear case collide. In a fast-expanding market, dilution can be survivable when the money funds growth that outpaces the share count. That is not what is happening here. This dilution funds a drug that generates no revenue and is still years from any approval, in a company whose equity is already effectively at zero. The exception that makes dilution tolerable does not apply.

The economics that even good data can't fix

Step back and the deepest problem is the therapy's own shape. Autologous cell therapy is made one patient at a time — each dose built from that person's own immune cells in a dedicated manufacturing run. That is the business model that underlies approved CAR-T cancer drugs, which cost hundreds of thousands of dollars per course and are reserved for the sickest patients. It is the opposite of a medicine that could reach millions of people.

Alzheimer's is a chronic disease in a vast population. A therapy that must be manufactured per patient and redosed repeatedly — NKGen's moderate-Alzheimer's patients received a dose every three weeks — carries a cost and scale wall that no conference slide removes. Even if troculeucel proves effective in a proper placebo-controlled trial, selling it broadly at a price patients or payers can absorb is a problem the current technology does not solve.

The judgment

You can believe every word of the clinical data and still reach the same conclusion: NKGen is not, in its current form, a vehicle that rewards a retail shareholder. The stock's return is being determined by a financing cadence — near-zero cash, penny-priced convertible notes, warrants, and authorized-share votes — years before any efficacy readout could change the picture. The drug narrative may survive; the equity is being decided by the balance sheet, and the balance sheet is the weak link.

Demand for a dementia treatment is not the question. The question is whether this particular common stock can compound through the funding gauntlet required to find out — or whether your capital is better deployed where the operating results already exist. For a reader deciding whether to buy in, the discipline is the same one that governs any clinical-stage microcap: decide on delivered milestones and the capital structure that funds them, not on the promise and not on the presentation schedule.